Mentoring patient-oriented researchers in pediatric diarrhea

指导以患者为中心的小儿腹泻研究人员

基本信息

  • 批准号:
    10591728
  • 负责人:
  • 金额:
    $ 17.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-11 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary Diarrheal illness is the second most common cause of non-neonatal death among young children worldwide, and is a major cause of morbidity. Current etiologic diagnosis of diarrhea relies on microbial detection, and decisions for antibiotics commonly empiric. However, the majority of cases of diarrhea do not benefit from antibiotic use, and testing for all potential pathogens is neither financially nor logistically feasible. Thus, methods to improve the clinical management of pediatric diarrheal illness, including strategies for antimicrobial and diagnostic stewardship, are needed. Clinical prediction rules are potential tools to address this need, and in this K24 application, our overall goal is to explore strategies to improve clinical decision-making for diarrhea management, through use of spatial-temporal data and biomarkers. Dr. Leung, the PI, is a physician-scientist with training in clinical infectious diseases, immunology, microbiology, and epidemiology, with a focus on enteric infections, especially those that cause diarrheal illness in children in limited-resource settings. He has mentored over 40 patient-oriented researchers (PORs) since the start of his independent research program in 2014; additionally, he has co-mentored numerous PORs in collaboration with scientists and clinicians working in low- and middle-income countries. Leveraging infrastructure already in place from three ongoing NIH-funded awards (R01AI130378, R01AI135114, R01AI135115), as well as Gates Foundation-funded studies, he proposes to augment his current POR by addressing the following aims: 1) To examine the use of spatial- temporal data for individual-level clinical prediction of pediatric diarrhea, where the use of A) serosurveillance, B) molecular diagnostic, and C) earth observation-derived data will be explored, and 2) To identify clinical use- cases, and potential candidates, of fecal biomarkers that complement clinical decision support tools for management of pediatric diarrhea, using both qualitative methods to examine end-user perspectives and identify use-cases, and metabolomics and transcriptomics methods to identify candidate biomarkers. To accomplish these aims, he has established a co-mentoring team of experienced investigators with diverse expertise in statistical methods, biomarker discovery, and mentoring of POR investigators. This award will provide protected time for Dr. Leung to improve and increase his mentoring capacity of POR trainees, expand his expertise and experience in bioinformatics, and generate data for future projects to improve the management and knowledge of pediatric diarrheal infections.
项目摘要 腹泻病是全世界幼儿非新生儿死亡的第二大常见原因, 并且是发病的主要原因。目前腹泻的病原学诊断依赖于微生物检测, 抗生素的决定通常是经验性的。然而,大多数腹泻病例并不能从 抗生素的使用和对所有潜在病原体的检测在财政上和后勤上都不可行。因此,在本发明中, 方法,以改善临床管理的儿科腹泻病,包括战略, 和诊断管理是必要的。临床预测规则是解决这一需求的潜在工具, 在K24应用中,我们的总体目标是探索改善腹泻临床决策的策略 管理,通过使用时空数据和生物标志物。梁博士,PI,是一个物理学家,科学家 接受过临床传染病、免疫学、微生物学和流行病学方面的培训,重点是 肠道感染,特别是那些在资源有限的环境中导致儿童腹泻的疾病。他 自2004年开始独立研究计划以来,他指导了40多名以患者为导向的研究人员(PORs)。 2014年;此外,他还与科学家和临床医生合作,共同指导了许多POR, 在低收入和中等收入国家。利用NIH资助的三个正在进行的 奖项(R 01 AI 130378,R 01 AI 135114,R 01 AI 135115),以及盖茨基金会资助的研究,他 建议通过解决以下目标来增强其当前的POR:1)研究空间的使用- 儿童腹泻个体水平临床预测的时间数据,其中使用A)血清监测, B)分子诊断,和C)地球观测衍生的数据将被探索,和2)为了确定临床用途- 粪便生物标志物的病例和潜在候选者,补充临床决策支持工具, 儿科腹泻的管理,使用定性方法来检查最终用户的观点, 确定用例,以及代谢组学和转录组学方法,以确定候选生物标志物。到 为了实现这些目标,他建立了一个由经验丰富的调查人员组成的联合指导团队, 统计方法、生物标志物发现和POR研究人员指导方面的专业知识。这个奖项将 为梁博士提供受保护的时间,以改善和增加他对POR学员的指导能力, 他在生物信息学方面的专业知识和经验,并为未来的项目生成数据,以改善 管理和知识的儿科尿道感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Ted Leung其他文献

Daniel Ted Leung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Ted Leung', 18)}}的其他基金

Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    10522523
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    10132972
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    9912094
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    10649542
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
  • 批准号:
    9912093
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
  • 批准号:
    10388296
  • 财政年份:
    2018
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    10153667
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    9926810
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
  • 批准号:
    9398501
  • 财政年份:
    2017
  • 资助金额:
    $ 17.19万
  • 项目类别:
Immune responses to Vibrio cholerae in children
儿童对霍乱弧菌的免疫反应
  • 批准号:
    8517006
  • 财政年份:
    2012
  • 资助金额:
    $ 17.19万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 17.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了